NOTICE

HOME arrow MEDIA arrow NOTICE
Huons’ dry power inhaler Zephirus cleared for sales in Korea file -

South Korean pharmaceutical company Huons Co. said Monday it has won marketing approval from the Ministry of Food and Drug Safety for its Zephirus capsule, an asthema treatment developed by Belgium-based Laboratoires SMB S.A., in Korea. 

Zephirus is a fixed-dose combination of Budesonide, an inhaled corticosteroid formulation that alleviates lung inflammation, and Salmeterol Xinafoate, a persistent long-acting b2-agonist characterized by a rapid bronchodilation effect. 

 

PREV Jeju Air to revive Jeju-Fukuoka route in July
NEXT Samsung Elec looks to further apply blockchain technology in handset devices